JP6157481B2 - 芳香族陽イオン性ペプチドおよびその使用方法 - Google Patents

芳香族陽イオン性ペプチドおよびその使用方法 Download PDF

Info

Publication number
JP6157481B2
JP6157481B2 JP2014533434A JP2014533434A JP6157481B2 JP 6157481 B2 JP6157481 B2 JP 6157481B2 JP 2014533434 A JP2014533434 A JP 2014533434A JP 2014533434 A JP2014533434 A JP 2014533434A JP 6157481 B2 JP6157481 B2 JP 6157481B2
Authority
JP
Japan
Prior art keywords
renal
revascularization
peptide
subject
aras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014533434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530212A (ja
JP2014530212A5 (cg-RX-API-DMAC7.html
Inventor
ディー トラビス ウィルソン
ディー トラビス ウィルソン
リラク オー レルマン
リラク オー レルマン
スティーブン シー テクスター
スティーブン シー テクスター
Original Assignee
メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ
メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ
ステルス ペプチドズ インターナショナル インコーポレイテッド
ステルス ペプチドズ インターナショナル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ, メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ, ステルス ペプチドズ インターナショナル インコーポレイテッド, ステルス ペプチドズ インターナショナル インコーポレイテッド filed Critical メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ
Publication of JP2014530212A publication Critical patent/JP2014530212A/ja
Publication of JP2014530212A5 publication Critical patent/JP2014530212A5/ja
Application granted granted Critical
Publication of JP6157481B2 publication Critical patent/JP6157481B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014533434A 2011-09-29 2012-09-28 芳香族陽イオン性ペプチドおよびその使用方法 Active JP6157481B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161540910P 2011-09-29 2011-09-29
US61/540,910 2011-09-29
US201161558177P 2011-11-10 2011-11-10
US61/558,177 2011-11-10
US201261596455P 2012-02-08 2012-02-08
US61/596,455 2012-02-08
US201261642282P 2012-05-03 2012-05-03
US61/642,282 2012-05-03
US201261681444P 2012-08-09 2012-08-09
US61/681,444 2012-08-09
PCT/US2012/058091 WO2013049697A1 (en) 2011-09-29 2012-09-28 Aromatic-cationic peptides and methods for using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111807A Division JP6465927B2 (ja) 2011-09-29 2017-06-06 芳香族陽イオン性ペプチドおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2014530212A JP2014530212A (ja) 2014-11-17
JP2014530212A5 JP2014530212A5 (cg-RX-API-DMAC7.html) 2015-11-12
JP6157481B2 true JP6157481B2 (ja) 2017-07-05

Family

ID=47996475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014533434A Active JP6157481B2 (ja) 2011-09-29 2012-09-28 芳香族陽イオン性ペプチドおよびその使用方法
JP2017111807A Active JP6465927B2 (ja) 2011-09-29 2017-06-06 芳香族陽イオン性ペプチドおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017111807A Active JP6465927B2 (ja) 2011-09-29 2017-06-06 芳香族陽イオン性ペプチドおよびその使用方法

Country Status (8)

Country Link
US (3) US9988422B2 (cg-RX-API-DMAC7.html)
EP (1) EP2760460B1 (cg-RX-API-DMAC7.html)
JP (2) JP6157481B2 (cg-RX-API-DMAC7.html)
CN (3) CN107496899A (cg-RX-API-DMAC7.html)
AU (3) AU2012315586B2 (cg-RX-API-DMAC7.html)
CA (2) CA3123992C (cg-RX-API-DMAC7.html)
HK (1) HK1249406A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013049697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107496899A (zh) * 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CA2920020C (en) * 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2016004067A1 (en) * 2014-06-30 2016-01-07 Stealth Biotherapeutics Corp Aromatic-cationic peptide formulations, compositions and methods of use
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
CA3010321A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
IL305687B2 (en) * 2017-12-15 2024-12-01 Stealth Biotherapeutics Inc Mitochondria-targeting peptides
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
FR3079142B1 (fr) * 2018-03-23 2020-11-27 Matieres Premieres Int Composition veterinaire comprenant de la superoxyde dismutase et au moins un hydrolysat de proteines riche en peptides bioassimilables
US12002199B2 (en) * 2018-09-28 2024-06-04 The Board Of Regents Of The University Of Texas System Methods, apparatuses, and systems for 3-D phenotyping and physiological characterization of brain lesions and surrounding tissue
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
JP2024521373A (ja) * 2021-06-01 2024-05-31 アイディア バイオ，エルエルシー 硝子体内ミトコンドリア標的化ペプチドプロドラッグおよび使用方法
CN113718029A (zh) * 2021-10-22 2021-11-30 中国人民解放军北部战区总医院 S100a4蛋白在动脉粥样硬化性肾动脉狭窄诊断中的应用
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4491132A4 (en) * 2022-03-31 2025-06-18 Terumo Kabushiki Kaisha PROGRAM, INFORMATION PROCESSING METHOD AND INFORMATION PROCESSING DEVICE

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DK72587D0 (da) 1987-02-13 1987-02-13 Carlsberg Biotechnology Ltd Fremgangsmaade til enzymatisk fremstilling af dipeptider
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5573957A (en) * 1994-09-28 1996-11-12 Spectral Diagnostics, Inc. Monoclonal antibody to human cardiac myoglobin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
FR2771010B1 (fr) * 1997-11-19 2003-08-15 Adir Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2000044365A1 (en) 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methods for preventing graft rejection and ischemia-reperfusion injury
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CA2562957C (en) 2004-03-31 2013-05-21 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
CA2655144A1 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
US20100305183A1 (en) * 2006-12-08 2010-12-02 Adelaide Research & Innovation Pty Ltd Method and composition for reducing reperfusion injury
EP2120782B1 (en) 2007-01-03 2018-10-10 Boston Scientific Scimed, Inc. Pelvic implant
AU2008306264A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
JP2010538991A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのｓｆｌｌｒ−ｏｈおよびムラミルジペプチドの使用
CN107802821A (zh) 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
GB0805912D0 (en) 2008-04-01 2008-05-07 Bioalvo Servi Os Investiga Oo Treatment
GB0805862D0 (en) 2008-04-01 2008-04-30 Bioalvo Servi Os Investiga Oo Method
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2311554A1 (en) 2009-10-07 2011-04-20 Linde Aktiengesellschaft Method for reaction control of exothermic reaction and apparatus therefore
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN107496899A (zh) * 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CA2858550A1 (en) 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US20150119552A1 (en) 2012-04-12 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same

Also Published As

Publication number Publication date
CA3123992A1 (en) 2013-04-04
EP2760460A1 (en) 2014-08-06
WO2013049697A1 (en) 2013-04-04
US11420998B2 (en) 2022-08-23
AU2012315586B2 (en) 2017-07-20
EP2760460A4 (en) 2015-06-24
CA2850520A1 (en) 2013-04-04
AU2017248477A1 (en) 2017-11-09
AU2018253546A1 (en) 2018-11-22
US20140235529A1 (en) 2014-08-21
CN106913860A (zh) 2017-07-04
JP2017165772A (ja) 2017-09-21
CN103987397A (zh) 2014-08-13
US20180327450A1 (en) 2018-11-15
AU2012315586A1 (en) 2014-05-08
WO2013049697A9 (en) 2014-08-07
HK1249406A1 (zh) 2018-11-02
JP2014530212A (ja) 2014-11-17
CN107496899A (zh) 2017-12-22
US20200223887A1 (en) 2020-07-16
JP6465927B2 (ja) 2019-02-06
AU2017248477B2 (en) 2018-08-02
EP2760460B1 (en) 2019-11-20
CA2850520C (en) 2021-08-31
US9988422B2 (en) 2018-06-05
CA3123992C (en) 2024-06-04

Similar Documents

Publication Publication Date Title
JP6465927B2 (ja) 芳香族陽イオン性ペプチドおよびその使用方法
JP7382607B2 (ja) 心不全の予防又は処置の方法
US10322159B2 (en) Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
JP2016210801A (ja) 熱傷及び二次性合併症の予防及び治療方法
EP3256143A2 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
CA2916497C (en) Methods for the regulation of matrix metalloproteinase expression

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170606

R150 Certificate of patent or registration of utility model

Ref document number: 6157481

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250